LON:CSRT - Consort Medical plc (CSRT.L) Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1,010
▲ +5 (0.50%)
1 month | 3 months | 12 months
Get New Consort Medical plc (CSRT.L) Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CSRT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CSRT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
GBX 0
▼ -100.00% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Consort Medical plc (CSRT.L) in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 1,010.
Hold
The current consensus among 1 polled investment analysts is to hold stock in Consort Medical plc (CSRT.L). This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
7/25/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
10/23/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
1/21/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
4/20/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
7/19/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
10/17/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/15/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetDetails
2/10/2020Royal Bank of CanadaUpgradeSector Performer
i
1/10/2020Royal Bank of CanadaDowngradeUnderperformGBX 1,200 ➝ GBX 1,010
i
11/19/2019Royal Bank of CanadaBoost Price TargetOutperformGBX 1,060 ➝ GBX 1,200
i
11/18/2019Shore CapitalDowngradeHold
i
10/18/2019Shore CapitalUpgradeBuy
i
9/27/2019Shore CapitalUpgradeBuy
i
9/11/2019Shore CapitalDowngradeHold
i
7/15/2019Shore CapitalReiterated RatingBuy
i
6/13/2019Royal Bank of CanadaLower Price TargetOutperformGBX 1,320 ➝ GBX 1,130
i
6/13/2019Shore CapitalReiterated RatingBuy
i
6/6/2019Numis SecuritiesDowngradeHold
i
1/31/2019Shore CapitalReiterated RatingBuy
i
1/21/2019Shore CapitalUpgradeBuy
i
12/4/2018Shore CapitalLower Price TargetHoldGBX 1,255 ➝ GBX 1,215
i
12/4/2018Royal Bank of CanadaUpgradeOutperformGBX 1,430 ➝ GBX 1,320
i
9/10/2018Shore CapitalReiterated RatingHold
i
7/2/2018Shore CapitalDowngradeHold
i
2/8/2018Numis SecuritiesUpgradeAddGBX 1,333
i
12/6/2017Numis SecuritiesBoost Price TargetHoldGBX 1,084 ➝ GBX 1,144
i
12/5/2017Shore CapitalReiterated RatingBuy
i
12/5/2017N+1 SingerDowngradeHold
i
11/9/2017Stifel NicolausReiterated RatingBuyGBX 1,250
i
6/15/2017Numis SecuritiesReiterated RatingHoldGBX 1,084
i
6/15/2017Panmure GordonReiterated RatingBuyGBX 1,145
i
6/15/2017Stifel NicolausReiterated RatingHoldGBX 1,100
i
6/15/2017InvestecReiterated RatingBuyGBX 1,165
i
6/15/2017N+1 SingerReiterated RatingBuyGBX 1,125
i
6/15/2017Shore CapitalReiterated RatingBuy
i
4/4/2017Stifel NicolausReiterated RatingBuyGBX 1,150
i
4/4/2017Numis SecuritiesInitiated CoverageHoldGBX 1,084
i
3/30/2017Shore CapitalReiterated RatingBuy
i
1/26/2017Panmure GordonReiterated RatingBuyGBX 1,145
i
1/23/2017Canaccord GenuityReiterated RatingBuyGBX 1,300
i
1/23/2017Shore CapitalReiterated RatingBuy
i
1/3/2017Shore CapitalReiterated RatingBuy
i
1/3/2017Panmure GordonReiterated RatingBuyGBX 1,145
i
12/19/2016N+1 SingerUpgradeBuyGBX 1,067 ➝ GBX 1,125
i
12/7/2016Canaccord GenuityReiterated RatingBuyGBX 1,300
i
12/6/2016InvestecReiterated RatingBuyGBX 1,170
i
12/1/2016Canaccord GenuityReiterated RatingBuyGBX 1,300
i
9/20/2016Canaccord GenuityReiterated RatingBuyGBX 1,300
i
8/11/2016Canaccord GenuityReiterated RatingBuyGBX 1,300
i
7/29/2016Canaccord GenuityBoost Price TargetBuyGBX 1,150 ➝ GBX 1,300
i
6/17/2016Numis SecuritiesReiterated RatingUnder Review
i
6/16/2016Stifel NicolausReiterated RatingBuyGBX 1,200
i
6/16/2016InvestecBoost Price TargetBuyGBX 1,150 ➝ GBX 1,170
i
6/16/2016Canaccord GenuityReiterated RatingBuyGBX 1,150
i
6/16/2016Panmure GordonReiterated RatingBuyGBX 1,145
i
6/9/2016Panmure GordonReiterated RatingBuyGBX 1,145
i
6/2/2016Canaccord GenuityReiterated RatingBuyGBX 1,150
i
5/23/2016Canaccord GenuityReiterated RatingBuyGBX 1,150
i
4/26/2016Canaccord GenuityReiterated RatingBuyGBX 1,150
i
4/11/2016Canaccord GenuityReiterated RatingBuyGBX 1,150
i
4/4/2016Royal Bank of CanadaInitiated CoverageSector PerformerGBX 1,150
i
4/1/2016Canaccord GenuityReiterated RatingBuyGBX 1,150
i
3/24/2016Canaccord GenuityReiterated RatingBuyGBX 1,150
i
3/16/2016Canaccord GenuityBoost Price TargetBuyGBX 1,054 ➝ GBX 1,150
i
2/22/2016Canaccord GenuityReiterated RatingBuyGBX 1,054
i
2/22/2016Stifel NicolausReiterated RatingHold
i
2/22/2016Panmure GordonReiterated RatingBuyGBX 1,145
i
2/8/2016Canaccord GenuityReiterated RatingBuyGBX 1,054
i
1/19/2016Panmure GordonReiterated RatingBuyGBX 1,145
i
(Data available from 1/15/2016 forward)
Consort Medical plc (CSRT.L) logo
Consort Medical plc operates as a one-stop developer and manufacturer of drugs and premium drug delivery devices. It operates through two divisions, Bespak and Aesica. The company provides various life improving treatments to patients across worldwide through the design, development, and manufacture of medical devices for inhaled, injectable, nasal, and ocular drug delivery, as well as point of care diagnostics products. It also develops, formulates, and manufactures active pharmaceutical ingredients and finished dose drugs. Consort Medical plc was incorporated in 1946 and is headquartered in Hemel Hempstead, the United Kingdom.
Read More

Today's Range

Now: GBX 1,010
1,005
1,010

50 Day Range

MA: GBX 1,010
1,010
1,010

52 Week Range

Now: GBX 1,010
702
1,075

Volume

768 shs

Average Volume

520,697 shs

Market Capitalization

£504.60 million

P/E Ratio

127.85

Dividend Yield

2.75%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Consort Medical plc (CSRT.L)?

The following Wall Street analysts have issued reports on Consort Medical plc (CSRT.L) in the last twelve months: Royal Bank of Canada.

What is the current price target for Consort Medical plc (CSRT.L)?

0 Wall Street analysts have set twelve-month price targets for Consort Medical plc (CSRT.L) in the last year. has the lowest price target set, forecasting a price of £100,000 for Consort Medical plc (CSRT.L) in the next year.

What is the current consensus analyst rating for Consort Medical plc (CSRT.L)?

Consort Medical plc (CSRT.L) currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CSRT, but not buy more shares or sell existing shares.

What other companies compete with Consort Medical plc (CSRT.L)?

How do I contact Consort Medical plc (CSRT.L)'s investor relations team?

Consort Medical plc (CSRT.L)'s physical mailing address is Ste D, Breakspear Park, Breakspear Way, HEMEL HEMPSTEAD, HP2 4TZ, United Kingdom. The company's listed phone number is +44-1442-867920. The official website for Consort Medical plc (CSRT.L) is www.consortmedical.com.